Analysis of the Effects of Age in Biological Systems

David T Harris

doi:10.4172/2153-0777.1000e121

ISSN: 2153-0777

Journal of Bioengineering and Bioelectronics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Analysis of the Effects of Age in Biological Systems

David T Harris^*
Department of Immunobiology, University of Arizona, Tucson, Arizona, USA
Corresponding Author :	David T Harris, PhD Department of Immunobiology University of Arizona Tucson, Arizona, USA E-mail: davidh@email.arizona.edu
Received December 07, 2012; Accepted December 11, 2012; Published December 17, 2012
Citation: Harris DT (2013) Analysis of the Effects of Age in Biological Systems. J Biochips Tiss Chips 3:e121. doi:10.4172/2153-0777.1000e121
Copyright: © 2013 Harris DT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioengineering and Bioelectronics

View PDF Download PDF

Stem cells of various origins (hematopoietic, neural, mesenchymal, etc) obtained from younger donors seem to be superior to the same stem cells harvested from older donors [1]. Why? No one really seems to know. Some investigators have reported declining stem cell numbers with age, while others have shown no change, or even an increase in number with donor age. Almost all investigators agree however, that stem cells lose potency with increasing donor age, for unknown reasons [2-8]. Similar observations have been made concerning stem cells obtained from donors displaying chronic health conditions, particularly chronic inflammatory diseases, such as heart failure and autoimmune diseases. Again, it is unclear why these underlying conditions results in changes in stem cell potency.

Some time ago, looking at stem cell use in hematopoietic transplantation, my colleagues and I demonstrated that children transplanted with newborn cord blood stem cells had significantly longer telomeres in cells isolated from their blood than comparable children transplanted with adult stem cells [9]. Thus, recipients of young stem cell transplants would be less likely to undergo premature cellular aging than those receiving older cells, which would be particularly important in pediatric patients who might live for decades after transplantation. These results implied that the telomerase enzyme might be in part involved in maintaining stem cell function.

Similarly, numerous studies (including our own unpublished data) have indicated that MSCs isolated from older donors, as well as from patients with chronic disease conditions, are neither as prevalent (in terms of the number of cells in the sample), nor as potent as those isolated from younger, healthier donors [2-8]. MSCs collected from older or disease-afflicted donors seem less able to differentiate into different cell types, and more prone to dying during culture. Finally, similar observations have been made for neural stem cells [3].

If stem cell quality declines with donor age, then there should be concern when using adult stem cells for cell based therapies, either in regenerative medicine of for tissue engineering. The ability of older stem cells to respond to injury and disease may be compromised during aging, and could contribute to inferior tissue repair. A possible explanation for these observations is the accumulation of endogenous DNA damage, which is known to occur in a variety of cell types, and would be expected to limit the utility of aged stem cells; although no one really knows why.

Thus, it seems that the purveyors and utilizers of biochips and tissue chips would be ideally situated to uncover the reasons for these effects of aging. It should be possible using single cell and mixed cell/tissue populations to determine if the effects are cell intrinsic or extrinsic, due to changes at the transcriptional or translational level, or a result of secreted factors. Rapid, high-throughput analyses should be used to identify possible culprits in these processes, and then test the hypotheses for validity. Proper implementation of these tools should allow for more rapid, more economical, and more precise identification of druggable targets to counteract the effects of aging on our stem cells.

References